Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical issues in current drug therapy for dementia.

H Förstl1

  • 1Department of Psychiatry and Psychotherapy, Technical University Munich, Germany.

Alzheimer Disease and Associated Disorders
|June 13, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Behavioral variant frontotemporal dementia: advanced disease stages and death. A step to palliative care.

International journal of geriatric psychiatry·2016
Same author

[Connections between sleep and Alzheimer's disease : Insomnia, amnesia and amyloid].

Der Nervenarzt·2016
Same author

[Mechanisms of Alzheimer's disease : Neuronal hyperactivity and hypoactivity as new therapeutic targets].

Der Nervenarzt·2016
Same author

[The burn-out syndrome: prevalence, symptoms, differential diagnosis and treatment].

Deutsche medizinische Wochenschrift (1946)·2014
Same author

Over-the-counter-drugs for the treatment of mood and anxiety disorders--the views of German pharmacists.

Pharmacopsychiatry·2014
Same author

Pathways and patterns of cell loss in verified Alzheimer's disease: a factor and cluster analysis of clinico-pathological subgroups.

Behavioural neurology·2014
Same journal

More Publications Needed on Cognitively Impaired-Not MCI: Call for Papers.

Alzheimer disease and associated disorders·2026
Same journal

CHMP2B p.Ala30Ser Variant in Biomarker-Confirmed Early-Onset Alzheimer Disease: A Potential Endolysosomal Disease Modifier.

Alzheimer disease and associated disorders·2026
Same journal

Early Gut Microbiome Alterations in Mild Cognitive Impairment Reflect Changes in Alzheimer Disease.

Alzheimer disease and associated disorders·2026
Same journal

Improvements in Cogstate Test Performance Depend on Number and Frequency of Prior Tests: Evidence from a Randomized Follow-Up Design.

Alzheimer disease and associated disorders·2026
Same journal

Identification of Functional lncRNAs in Alzheimer Disease by Integrative Analysis of lncRNA-mRNA Network Based on Competing Endogenous RNA Mechanism.

Alzheimer disease and associated disorders·2026
Same journal

Valacyclovir Treatment in Mild Cognitive Impairment: The VALMCI Randomized Clinical Trial.

Alzheimer disease and associated disorders·2026
See all related articles

Alzheimer disease diagnosis and treatment guidelines often neglect general practice realities, delaying effective dementia care. Future strategies focus on early identification of cognitive impairment risk.

Area of Science:

  • Neurology
  • Geriatrics
  • Pharmacology

Background:

  • Alzheimer disease is a prevalent cause of dementia.
  • Current expert guidelines for Alzheimer disease diagnosis and treatment may not align with general practice resources.
  • Focusing solely on pure Alzheimer disease overlooks the commonality of mixed dementia in older adults.

Purpose of the Study:

  • To evaluate the applicability of current Alzheimer disease guidelines in general practice.
  • To discuss challenges in the diagnosis and treatment of dementia, including mixed dementia cases.
  • To examine prescribing patterns and criteria for discontinuing antidementia drugs.

Main Methods:

  • Analysis of expert guidelines for Alzheimer disease diagnosis and treatment.
  • Review of drug sales data and prescribing attitudes in Germany.

Related Experiment Videos

  • Discussion of current symptomatic treatments and future diagnostic strategies.

    • Main Results:

    • Guidelines may delay treatment initiation until conservative dementia criteria are met.
    • Criteria for discontinuing antidementia drugs are questionable.
    • Prescribers often favor Ginkgo biloba and memantine over acetylcholinesterase inhibitors, potentially due to disappointment and financial constraints.
    • Early diagnosis and treatment of other dementia causes are successful, but symptomatic Alzheimer disease treatments remain unsatisfactory.

    Conclusions:

    • Current Alzheimer disease guidelines require adaptation for general practice settings.
    • There is a need for revised criteria for initiating and discontinuing antidementia drug therapy.
    • Future research should focus on early identification models for individuals at high risk of cognitive impairment.